Related Experiment Video
Updated: Dec 18, 2025
In Vitro Model of Coronary Angiogenesis
Published on: March 10, 2020
Heart-derived fibroblasts express LYPD-1 and negatively regulate angiogenesis in rat
Satoru Sakamoto1,2, Katsuhisa Matsuura1,2, Shinako Masuda1
1Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan.
Insights
Heart fibroblasts express LYPD-1, an anti-angiogenic factor, inhibiting blood vessel formation. This mechanism is conserved in rats and may be impaired in heart disease, offering therapeutic potential for cardiac tissue engineering.
Area of Science:
- Cardiovascular Biology
- Cell Biology
- Tissue Engineering
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tissue repair and development.
- While pro-angiogenic factors in ischemic heart disease are well-studied, inhibitory mechanisms remain less understood.
- LYPD-1 was recently identified as a novel anti-angiogenic factor from human heart fibroblasts.
Purpose of the Study:
- To investigate the role of LYPD-1 in angiogenesis in mammalian hearts.
- To determine if LYPD-1 expression and function are conserved across species.
- To explore the implications of LYPD-1 in ischemic heart disease and cardiac tissue engineering.
Main Methods:
- Fibroblast isolation and culture from neonatal and adult rat hearts.
- Co-culture assays to assess endothelial cell network formation.
- Immunohistochemical analysis of LYPD-1 distribution in rat heart tissue.
- Quantitative analysis of LYPD-1 mRNA expression in myocardial infarction models.
Main Results:
- Rat heart fibroblasts express LYPD-1 and inhibit endothelial network formation, similar to human fibroblasts.
- LYPD-1 is predominantly found in interstitial tissues of the rat heart, with consistent expression from development to adulthood.
- LYPD-1 mRNA expression significantly decreased in a rat model of myocardial infarction.
- These findings suggest reduced angiogenesis-inhibitory mechanisms in ischemic heart conditions.
Conclusions:
- The heart exhibits relatively low inherent angiogenicity due to high LYPD-1 expression by fibroblasts, a mechanism conserved in rats.
- Downregulation of LYPD-1 in myocardial infarction may indicate insufficient suppression of anti-angiogenic mechanisms, hindering compensatory angiogenesis.
- Further understanding of LYPD-1's regulatory pathways could pave the way for novel angiogenic therapies for ischemic heart diseases and advancements in bioengineered cardiac tissues.
Abstract:
Angiogenesis is regulated by a balance between promoting and inhibitory mechanisms. Although angiogenesis-promoting mechanisms have been well studied in ischemic heart diseases, angiogenesis-inhibitory mechanisms have not. Recently, we identified LYPD-1 as a novel anti-angiogenic factor derived from human heart-derived fibroblasts, which suppresses endothelial cell network formation in co-culture. However, it remains unclear whether the low angiogenicity of heart-derived fibroblasts with high expression of LYPD-1 is also observed in other mammalian species, and the properties of LYPD-1 under normal and pathological conditions remain elusive. Fibroblasts isolated from neonatal and adult rat heart also express LYPD-1 and inhibit endothelial network formation in co-culture. Moreover, immunohistochemical analysis revealed that LYPD-1 was predominantly observed in the interstitial tissues of rat heart and LYPD1 expression levels were identical from late developmental period to adult. Conversely, LYPD-1 mRNA expression was significantly downregulated temporally in myocardial infarction model rats, suggesting that angiogenesis-inhibitory mechanisms might not be sufficiently suppressed to promote angiogenesis in ischemic heart diseases. These findings suggest that heart has relatively low angiogenicity compared with other organs via the high expression of LYPD-1 by fibroblasts. Moreover, understanding the regulatory mechanisms of LYPD-1-mediated inhibition of angiogenesis might lead a novel angiogenic therapy for ischemic heart diseases and contribute to development of bioengineered cardiac tissue.
